[Neurohumoral changes in patients with heart failure treated chronically with beta-blockers].
Long-term beta-blocker therapy may be useful in some patients affected by chronic heart failure. In a group of 15 patients with chronic heart failure of different origin we evaluated clinical, hemodynamic and neurohormonal features after 1 year of therapy. All patients were treated with atenolol at dosage of 50 mg/die. We observed a better ejection fraction by radionuclide angiography after 1 year of treatment. There was an increase of exercise time and VO2 max evaluated by cycloergometer test. There was a decrease of mean pulmonary artery pressure, of pulmonary vascular resistance and of right atrial pressure. Plasmatic norepinephrine decreased from 1294 +/- 568 to 574 +/- 33 pg/l. Our results suggest that patients who well tolerated chronic beta-blockade show an improvement of performance parameters.
Cattedra di Malattie Cardiovascolari, Università degli Studi, Modena.
A V
AV
Mattioli
G
G
Mattioli
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001262:Atenolol / Q000008:administration & dosage; D002908:Chronic Disease; D004070:Digitalis; D004232:Diuretics / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000097:blood*; D010946:Plants, Medicinal; D010947:Plants, Toxic
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D018377:Neurotransmitter Agents; D001262:Atenolol
Modificazioni neurormonali in pazienti con insufficienza cardiaca trattata cronicamente con betabloccanti.